ClinicalTrials.gg
Status unknownNCT04785833Updated Mar 8, 2021

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

An interventional study of T cell injection targeting CD7 chimeric antigen receptor in T-ALL, sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-08.

Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 27 open to participants now, 28 under way, 4 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
31st of 50
20 · median 30
Started
2021
with 4 others
No phase
3 of 51
1 open now
Registered
12th of 51
by date
Lead sponsor
4 of 51
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Among the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 31st largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2021, is one of 3 with no phase, and was the 12th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

27 of the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

Patients with acute leukemia derived from T lymphocytes have the characteristics of high expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to genetically modify the patient's T lymphocytes to target and eliminate tumor cells in a major histocompatibility complex-independent manner. CAR-T cells are costimulatory molecules that include single-chain antibodies (scFv) that recognize tumor-specific antigens, hinge regions, transmembrane regions, intracellular signaling regions (immunoreceptor tyrosine activation motif ITAM), and intracellular signaling regions. The chimeric antigen receptor of CD28 or CD137(4-1BB) conduction domain is expressed in a lentiviral vector, and the vector is transfected into autologous T cells, so that the modified CAR-T cells have targeting and specificity Recognizes and kills cancer cells expressing tumor antigens, and can proliferate and activate in vivo, but has no effect on cells that do not express the antigen

03

Conditions studied

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12-65
  • Sign
  • Expected survival time ≥ 3 months
  • CD7 positive and relapsed acute leukemia
  • score≥60
  • score ≤ 2
  • Have not received other immunotherapy within 3 months
  • The CD7 expression rate on the surface of leukemia cells detected by flow cytometry is greater than 30%

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled active infection
  • Active viral or C
  • test positive
  • Congenital immunodeficiency patients
  • Pregnant and breastfeeding patients
  • Patients with central nervous system tumors or central nervous system leukemia
  • The patient and/or family members do not agree to the treatment plan
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    T cell injection targeting CD7 chimeric antigen receptor

    Drug: T cell injection targeting CD7 chimeric antigen receptor

Interventions

  • Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation

06

What researchers measure

Primary outcomes

  1. DLT

    Dose-limiting toxicity

    Time frame: Up to 2 years

Secondary outcomes

  1. Safety results

    Number of adverse events

    Time frame: Up to 2 years

  2. PK

    The maximum concentration (Cmax)

    Time frame: Up to 2 years

  3. PD

    Absolute value of CD7 Positive Cells in peripheral blood at each time point

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • The First Affiliared Hospital Of SOOCHOW University
    Suzhou, Jiangsu 215006, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2021; primary completion for Apr 2022, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 8, 2021
StartEst.
Mar 4, 2021
Primary completionEst.
Apr 30, 2022
CompletionEst.
Feb 4, 2024
Last update
Mar 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04785833
Responsible party
Sponsor
First posted
Mar 8, 2021
Start date
Mar 4, 2021 (estimated)
Primary completion
Apr 30, 2022 (estimated)
Completion
Feb 4, 2024 (estimated)
Last update
Mar 8, 2021

Study contacts

xiaowen tang
Contact
xwtang1020@163.com
13913538266
huimin meng
Contact
huimin.meng@persongen.com.cn
18896802149

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD7 CAR T Cells PA3-17

Start the discussion